Development of a Long Acting and Stapled Dual Amylin and Calcitonin Receptor Agonist as Monotherapy and Combination with GLP 1R Agonists for the Treatment of Obesity Bioconjugate Chemistry PDF) Eloralintide, a selective, longacting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept The evolving landscape of obesity pharmacotherapy Nature Reviews Drug Discovery, 2026 1 Obesity pharmacotherapy has moved from weight loss drugs to cardiometabolic disease modifying therapy Obesity is now framed as a chronic, relapsing, Everyone and their mother is talking about eloralintide, the new amylin receptor agonist showing up to 20% body weight reduction in early trials. Gabriel Alizaidy, MD, MS Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48 week phase 2, multicentre, double blind, randomised, placebo controlled trial The Lancet